Cardiovascular regeneration stands at the forefront of transformative medical research, offering a paradigm shift in the treatment of heart-related ailments. In the relentless pursuit of innovative therapeutic strategies, scientists are exploring novel avenues to regenerate damaged cardiovascular tissues. Beyond traditional methods, cutting-edge technologies like CRISPR gene editing and precision medicine are being harnessed to customize treatments for individual patients. The evolving landscape of cardiovascular regeneration not only holds promise for repairing heart tissues but also for revolutionizing personalized medicine in the realm of cardiac care. By unlocking the regenerative potential within our own bodies and integrating groundbreaking technologies, the field of cardiovascular regeneration represents a beacon of hope for a future where heart health is not merely managed but actively restored.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States